English
中文繁體
中文简体

Dark
Light

Open Account

US OptionsDetailed Quotes

AXSM250516P180000

Watchlist

0.00
0.000.00%

15min DelayClose May 7 09:30 ET

0.00High0.00Low

Axsome Therapeutics Stock Discussion

Sign in to post a comment

$Axsome Therapeutics (AXSM.US)$ anyone know why axsome is dropping despite the good earnings?

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

$Axsome Therapeutics (AXSM.US)$
Axsome's MDD Drug Trial Reveals Unexpected Win in Sleepiness Subgroup

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

$Axsome Therapeutics (AXSM.US)$
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

$Axsome Therapeutics (AXSM.US)$
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

$Axsome Therapeutics (AXSM.US)$
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

$Axsome Therapeutics (AXSM.US)$
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

$Axsome Therapeutics (AXSM.US)$
Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

$Axsome Therapeutics (AXSM.US)$ watching this incase of catalyst here biopharmcatalys...
has options
nfa be careful

Oct 13, 2024 03:13

$Axsome Therapeutics (AXSM.US)$ wonder what the insitutional ownership was when it went from 2 to 110 lol

2

Sep 25, 2024 21:07

$Axsome Therapeutics (AXSM.US)$ why the sudden drop?

No comment yet